1![ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 – ISIS INITIATES PHASE 1 CLINICAL STUDY OF ISIS-SMNRX IN PATIENTS WITH SPINAL MUSCULAR ATROPHY U.S. FDA has granted both Fast Track Status and Orphan Drug Designation for ISIS-SMNRx CARLSBAD, Calif., December 19, 2011 –](https://www.pdfsearch.io/img/534b0b4a74c72646f0e001e1a28bc4fa.jpg) | Add to Reading ListSource URL: www.fsma.org.hkLanguage: English - Date: 2013-04-29 02:31:35
|
---|
2![HIGHLIGHTS OF PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION](https://www.pdfsearch.io/img/12ca01811c04d5e1367f477c3f0151a2.jpg) | Add to Reading ListSource URL: www.genzyme.comLanguage: English - Date: 2015-03-03 10:30:18
|
---|
3![MEDICATION GUIDE KYNAMRO® (kye-NAM-roe) (mipomersen sodium) injection Read this Medication Guide before you start using KYNAMRO and each time you get MEDICATION GUIDE KYNAMRO® (kye-NAM-roe) (mipomersen sodium) injection Read this Medication Guide before you start using KYNAMRO and each time you get](https://www.pdfsearch.io/img/dbb97aab96a289d509342db387ded028.jpg) | Add to Reading ListSource URL: www.genzyme.comLanguage: English - Date: 2015-01-31 20:53:04
|
---|
4![Microsoft PowerPoint - Genzyme_Adcom_Public slides for the FDA Microsoft PowerPoint - Genzyme_Adcom_Public slides for the FDA](https://www.pdfsearch.io/img/03b86409dec34eec2ddca276a221e799.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
5![Endocrinologic and Metabolic Drugs Advisory Committee Meeting Silver Spring, MD 18 October[removed]FDA Review of the Nonclinical Carcinogenicity Assessment Endocrinologic and Metabolic Drugs Advisory Committee Meeting Silver Spring, MD 18 October[removed]FDA Review of the Nonclinical Carcinogenicity Assessment](https://www.pdfsearch.io/img/32261e3bfee9aa945da121dad3dabd73.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
6![MARCH/APRIL 2014 VOL. 26 NO. 2 PEER REVIEW Perspective Visibility MARCH/APRIL 2014 VOL. 26 NO. 2 PEER REVIEW Perspective Visibility](https://www.pdfsearch.io/img/8320020065a7e0b7000888f1ee8e66bb.jpg) | Add to Reading ListSource URL: www.cshp.orgLanguage: English - Date: 2014-07-01 17:55:55
|
---|
7![Microsoft PowerPoint - Mipo_Core Presentation_10_18_12_FINAL SHOW FILE Microsoft PowerPoint - Mipo_Core Presentation_10_18_12_FINAL SHOW FILE](https://www.pdfsearch.io/img/b71a30c0ad3f2d2e49f01c63067c8093.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
8![Back-up Slides Ronald Wange, Ph.D. EMDAC October 18, 2012 meeting 18 October 2012 Back-up Slides Ronald Wange, Ph.D. EMDAC October 18, 2012 meeting 18 October 2012](https://www.pdfsearch.io/img/4e1fda7c4f2fd2683d809fcfcfa401f4.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
9![FDA Briefing Document NDA[removed]Mipomersen Sodium Injection 200 mg/mL Applicant: Genzyme Corporation FDA Briefing Document NDA[removed]Mipomersen Sodium Injection 200 mg/mL Applicant: Genzyme Corporation](https://www.pdfsearch.io/img/acd23429f8cb4c511da93a2290aaef8e.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
10![Microsoft Word - FINAL POSTING Questions EMDAC[removed]Mipomersen.docx Microsoft Word - FINAL POSTING Questions EMDAC[removed]Mipomersen.docx](https://www.pdfsearch.io/img/b8171ec6ea6bb4974f3cbc7c3621c7fa.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|